GT BIOPHARMA, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
GT BIOPHARMA, INC. (GTBP) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $46.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-14
- GT BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $46.00K, a 1050.00% increase year-over-year.
- GT BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $46.00K, a 1433.33% increase year-over-year.
- GT BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-12-31 was $46.00K, a 475.00% increase year-over-year.
- GT BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $379.00K.
- GT BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $432.00K, a 87.83% increase from fiscal 2024.
- GT BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $230.00K, a 87.01% decline from fiscal 2023.
- GT BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $1.77M, a 41.62% decline from fiscal 2022.
- GT BIOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $3.03M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $46.00K 10-Q · filed 2026-08-14 | $92.00K 10-Q · filed 2026-08-14 | $138.00K derived: sum of 3 quarters · filed 2026-08-14 | $517.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $46.00K 10-Q · filed 2026-05-15 | $92.00K derived: sum of 2 quarters · filed 2026-05-15 | $471.00K derived: sum of 3 quarters · filed 2026-05-15 | $475.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $46.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $425.00K derived: sum of 2 quarters · filed 2026-03-06 | $429.00K derived: sum of 3 quarters · filed 2026-08-14 | $432.00K 10-K · filed 2026-03-02 | |
| 2025-09-30 | $379.00K 10-Q/A · filed 2026-03-06 | $383.00K derived: sum of 2 quarters · filed 2026-08-14 | $386.00K 10-Q/A · filed 2026-03-06 | $394.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $4.00K 10-Q · filed 2026-08-14 | $7.00K 10-Q · filed 2026-08-14 | $15.00K derived: sum of 3 quarters · filed 2026-08-14 | $15.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $3.00K 10-Q · filed 2026-05-15 | $11.00K derived: sum of 2 quarters · filed 2026-05-15 | $11.00K derived: sum of 3 quarters · filed 2026-05-15 | $131.00K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $8.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $8.00K derived: sum of 2 quarters · filed 2026-03-06 | $128.00K derived: sum of 3 quarters · filed 2026-03-06 | $230.00K 10-K · filed 2026-03-02 | |
| 2024-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2026-03-06 | $120.00K derived: sum of 2 quarters · filed 2026-03-06 | $222.00K 10-Q/A · filed 2026-03-06 | $654.00K derived: sum of 4 quarters · filed 2026-03-06 | |
| 2024-06-30 | $120.00K 10-Q/A · filed 2026-03-06 | $222.00K 10-Q/A · filed 2026-03-06 | $654.00K derived: sum of 3 quarters · filed 2026-03-06 | $1.09M derived: sum of 4 quarters · filed 2026-03-06 | |
| 2024-03-31 | $102.00K 10-Q · filed 2025-05-15 | $534.00K derived: sum of 2 quarters · filed 2025-05-15 | $967.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.36M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $432.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $865.00K derived: sum of 2 quarters · filed 2025-02-21 | $1.26M derived: sum of 3 quarters · filed 2025-02-21 | $1.77M 10-K · filed 2025-02-21 | |
| 2023-09-30 | $433.00K 10-Q · filed 2024-11-14 | $831.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.34M 10-Q · filed 2024-11-14 | $1.34M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $398.00K 10-Q · filed 2024-08-14 | $905.00K 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | $507.00K 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | $3.03M 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |